The neurobiology of bipolar disorder: findings using human postmortem central nervous system tissue

References

• Hill C, Keks N, Roberts S, et al. Problem of diagnosis in postmortem brain studies of schizophrenia. American Journal of Psychiatry 1996; 153: 533–537
   PubMed Web of Science ®Google Scholar
• Dean B, Pavey G, McLeod M, Opeskin K, Keks N, Copolov D. A change in the density of [3H]flumazinil, but not [3H]muscimol binding, in Brodmann's area 9 from subjects with bipolar disorder. Journal of Affective Disorders 2001; 66: 147–158
   PubMed Web of Science ®Google Scholar
• Torrey E F, Webster M, Knable M, Johnston N, Yolken R H. The stanley foundation brain collection and neuropathology consortium. Schizophrenia Research 2000; 44: 151–155
   PubMed Web of Science ®Google Scholar
• Sachs G S. Decision tree for the treatment of bipolar disorder. Journal of Clinical Psychiatry 2003; 64(Suppl. 8)35–40
   PubMed Web of Science ®Google Scholar
• Licht R W. Drug treatment of mania: a critical review. Acta Psychiatrica Scandinavica 1998; 97: 387–397
   PubMed Web of Science ®Google Scholar
• Mirnics K. Microarrays in brain research: the good, the bad and the ugly. National Review of Neuroscience 2001; 2: 444–447
   PubMed Web of Science ®Google Scholar
• Edgar P F, Douglas J E, Cooper G J, Dean B, Kydd R, Faull R L. Comparative proteome analysis of the hippocampus implicates chromosome 6q in schizophrenia. Molecular Psychiatry 2000; 5: 85–90
   PubMed Web of Science ®Google Scholar
• Dean B. Understanding the pathology of schizophrenia: recent advances from the study of the molecular architecture of postmortem CNS tissue. Postgraduate Medical Journal 2002; 78: 142–148
   PubMed Web of Science ®Google Scholar
• Arango V, Underwood M D, Mann J J. Serotonin brain circuits involved in major depression and suicide. Progress in Brain Research 2002; 136: 443–453
   PubMed Web of Science ®Google Scholar
• Norregaard L, Gether U. The monoamine neurotransmitter transporters: structure, conformational changes and molecular gating. Current Opinions in Drug Discovery and Development 2001; 4: 591–601
   PubMedGoogle Scholar
• Danbolt N C. Glutamate uptake. Progress in Neurobiology 2001; 65: 1–105
   PubMed Web of Science ®Google Scholar
• Tamminga C A, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Current Drug Targets. CNS and Neurological Disorders 2002; 1: 141–147
   PubMedGoogle Scholar
• Raiteri M. Presynaptic autoreceptors. Journal of Neurochemistry 2001; 78: 673–675
   PubMed Web of Science ®Google Scholar
• Young L T, Warsh J J, Kish S J, Shannak K, Hornykeiwicz O. Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biological Psychiatry 1994; 35: 121–127
   PubMed Web of Science ®Google Scholar
• Dean B. Signal transmission, rather than reception, is the underlying neurochemical abnormality in schizophrenia. Australian and New Zealand Journal of Psychiatry 2000; 34: 560–569
   PubMed Web of Science ®Google Scholar
• Dean B, Scarr E, Pavey G, Copolov D. Studies on serotonergic markers in the human hippocampus: Changes in subjects with bipolar disorder. Journal of Affective Disorders 2003; 25: 65–69
   Google Scholar
• Dean B, Opeskin K, Pavey G, et al. [3H]paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. Journal of Neurochemistry 1995; 64: 1197–1202
   PubMed Web of Science ®Google Scholar
• Naylor L, Dean B, Opeskin K, et al. Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H] paroxetine. Journal of Neural Transmission. General Section 1996; 103: 749–757
   PubMed Web of Science ®Google Scholar
• Scarr E, Copolov D L, Dean B. A proposed pathological model in the hippocampus of subjects with schizophrenia. Clinical Experimental Pharmacological Physiology 2001; 28: 70–73
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhang L, Johnston N L, Torrey E F, Yolken R H. Serial analysis of gene expression in the frontal cortex of patients with bipolar disorder. British Journal of Psychiatry 2001; 41: s137–s141
   Google Scholar
• Meador-Woodruff J H, Hogg A J, Smith R E. Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Research Bulletin 2001; 55: 631–640
   PubMed Web of Science ®Google Scholar
• Petty F. GABA and mood disorders: a brief review and hypothesis. Journal of Affective Disorders 1995; 34: 275–281
   PubMed Web of Science ®Google Scholar
• Sigel E, Buhr A. The benzodiazepine binding site of GABAA receptors. Trends in Pharmacological Science 1997; 18: 425–429
   PubMed Web of Science ®Google Scholar
• Ciraulo D A, Knapp C M, LoCastro J, Greenblatt D J, Shader R I. A benzodiazepine mood effect scale: reliability and validity determined for alcohol-dependent subjects and adults with a parental history of alcoholism. American Journal of Drug and Alcohol Abuse 2001; 27: 339–347
   PubMed Web of Science ®Google Scholar
• Ferrier I N, MacMillan I C, Young A H. The search for the wandering thymostat: a review of some developments in bipolar disorder research. British Journal of Psychiatry 2001; 41: s103–s106
   Google Scholar
• Zhao T J, Li M, Chiu T H, Rosenberg H C. Decreased benzodiazepine binding with little effect on gamma-aminobutyric acid binding in rat brain after treatment with antisense oligodeoxynucleotide to the gamma-aminobutyric acid A receptor gamma-2 subunit. Journal of Pharmacological Experimental Therapy 1998; 287: 752–759
   PubMed Web of Science ®Google Scholar
• Avissar S, Schreiber G, Danon A, Belmaker R H. Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature 1988; 331: 440–442
   PubMed Web of Science ®Google Scholar
• Ozawa H, Rasenick M M. Coupling of the stimulatory GTP-binding protein Gs to rat synaptic membrane adenylate cyclase is enhanced subsequent to chronic antidepressant treatment. Molecular Pharmacology 1989; 36: 803–808
   PubMed Web of Science ®Google Scholar
• Freissmuth M, Waldhoer M, Bofill-Cardona E, Nanoff C. G protein antagonists. Trends in Pharmacological Science 1999; 20: 237–245
   PubMed Web of Science ®Google Scholar
• Friedman E, Wang H Y. Receptor-mediated activation of G proteins is increased in postmortem brains of bipolar affective disorder subjects. Journal of Neurochemistry 1996; 67: 1145–1152
   PubMed Web of Science ®Google Scholar
• Marinissen M J, Gutkind J S. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends in Pharmacological Science 2001; 22: 368–376
   PubMed Web of Science ®Google Scholar
• Young L T, Li P P, Kish S J, Siu K P, Warsh J J. Postmortem cerebral cortex Gs alpha-subunit levels are elevated in bipolar affective disorder. Brain Research 1991; 553: 323–326
   PubMed Web of Science ®Google Scholar
• Young L T, Li P P, Kish S J, Siu K P, Kamble A, Hornykiewicz O, Warsh J J. Cerebral cortex Gs alpha protein levels and forskolin-stimulated cyclic AMP formation are increased in bipolar affective disorder. Journal of Neurochemistry 1993; 61: 890–898
   PubMed Web of Science ®Google Scholar
• Mathews R, Li P P, Young L T, Kish S J, Warsh J J. Increased G alpha q/11 immunoreactivity in postmortem occipital cortex from patients with bipolar affective disorder. Biological Psychiatry 1997; 41: 649–656
   PubMed Web of Science ®Google Scholar
• Selbie L A, Hill S J. G protein-coupled-receptor cross-talk: the fine-tuning of multiple receptor-signalling pathways. Trends in Pharmacological Science 1998; 19: 87–93
   PubMed Web of Science ®Google Scholar
• Atack J R, Broughton H B, Pollack S J. Inositol monophosphatase –a putative target for Li+ in the treatment of bipolar disorder. Trends in Neuroscience 1995; 18: 343–349
   PubMed Web of Science ®Google Scholar
• Shimon H, Agam G, Belmaker R H, Hyde T M, Kleinman J E. Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. American Journal of Psychiatry 1997; 154: 1148–1150
   PubMed Web of Science ®Google Scholar
• Wang H Y, Friedman E. Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biological Psychiatry 1996; 40: 568–575
   PubMed Web of Science ®Google Scholar
• Rahman S, Li P P, Young L T, Kofman O, Kish S J, Warsh J J. Reduced [3H]cyclic AMP binding in postmortem brain from subjects with bipolar affective disorder. Journal of Neurochemistry 1997; 68: 297–304
   PubMed Web of Science ®Google Scholar
• Doskeland S O, Ogreid D. Binding proteins for cyclic AMP in mammalian tissues. International Journal of Biochemistry 1981; 13: 1–19
   PubMedGoogle Scholar
• Ichimiya T, Suhara T, Sudo Y, et al. Serotonin transporter binding in patients with mood disorders: a PET study with [11C] (+) McN5652. Biological Psychiatry 2002; 51: 715–722
   PubMed Web of Science ®Google Scholar
• Drevets W C, Frank E, Price J C, et al. PET imaging of serotonin 1A receptor binding in depression. Biological Psychiatry 1999; 46: 1375–1387
   PubMed Web of Science ®Google Scholar
• Suhara T, Nakayama K, Inoue O, et al. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology (Berlin) 1992; 106: 14–18
   PubMed Web of Science ®Google Scholar